Introduction
============

Perioperative acute kidney injury (AKI) is an abrupt deterioration of renal function that occurs as a complication of major cardiothoracic, vascular and transplant surgery \[[@B1]-[@B5]\]. In this setting AKI is associated with prolonged hospitalization and mortality rates as high as 60% \[[@B6],[@B7]\]; including a 25-fold increase in mortality following cardiac valve surgery \[[@B7],[@B8]\]. Furthermore, patients who sustain AKI and make a full recovery retain a higher risk of long-term mortality \[[@B9]\].

Among its diverse etiologic factors, ischemia-reperfusion injury (IRI) remains the foremost cause of perioperative AKI \[[@B10]\]. Following a transient deprivation of total or regional vascular supply to the kidney, restoration of blood flow inflicts continuous and severe damage in the post-ischemic renal parenchyma, characterized histopathologically as vascular, tubular, and inflammatory perturbations \[[@B11]\]. A growing body of evidence demonstrates that the TLR family, particularly TLR-4, plays the dominant role in mediating the deleterious effects in renal IRI \[[@B12],[@B13]\]. In addition, damage-associated molecules such as HMGB-1 have been postulated as a TLR-4 ligand that drives the robust inflammatory response in post-ischemic kidney \[[@B14],[@B15]\].

The current clinical management of perioperative AKI is supportive \[[@B16]\]; therefore, novel prophylactic (pre-insult therapy) and therapeutic (post-insult therapy) is required to reduce the burden of AKI in the perioperative period. The α~2~adrenoceptor agonist dexmedetomidine exerts sedative, analgesic, hemodynamic stabilizing, anti-inflammatory and diuretic effects \[[@B17]\]. It is a highly potent α~2~adrenergic agonist with a remarkable binding specificity for the α~2~adrenoceptor. Novel organoprotective properties of dexmedetomidine have been explored in the brain, heart and renal injury \[[@B18]-[@B21]\]. Indeed α~2~adrenoceptors are distributed widely in the renal proximal, distal tubules and peri-tubular vasculature. Clinically α~2~adrenoceptor agonists enhance urine flow rate and perioperative renal function \[[@B22],[@B23]\]; however, the underlying molecular mechanisms remain unknown. Animal studies have suggested that α~2~adrenoceptor agonists are renoprotective as a class; their mechanism largely revolving around modulating vasoreactivity \[[@B21],[@B24],[@B25]\]. Herein we report that dexmedetomidine protects against IRI to the kidney in mice and that the mechanism is due to a decrease in the level of renal cell death and suppression in the HMGB-1-TLR-4 inflammatory circuit.

Materials and methods
=====================

Cell line
---------

A stabilised cell line of kidney cells (HK2), derived from adult human kidney proximal tubular cells, was used in our experiments (European Cell Culture Collection, Salisbury, UK). Cells were cultured in RPMI 1640 medium, 1% L-glutamine 100 nM, 1% penicillin-streptomycin 100 U/ml, 5% fetal calf serum (Gibco, Invitrogen Ltd, Paisley, UK) in a humidified atmosphere containing 5% CO~2~. They were used soon after reaching 80% confluence.

Cell treatments
---------------

Cell injury was provoked by oxygen glucose deprivation (OGD) as we reported previously \[[@B26]\]. Briefly, OGD solution (116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO~4~, 1.0 mM NaH~2~PO~4~, 26 mM NaHCO~3~and 1.8 mM CaCl~2~; pH 7.4) was bubbled through with pure nitrogen gas for 15 minutes using sterile Drechsel bottles to remove oxygen from the solution. Cells were washed sequentially with warmed HEPES buffer solution (120 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl~2~, 1.8 mM CaCl~2~, 15 mM anhydrous D-glucose and 20 mM HEPES) and warmed prepared OGD solution. The multi-well plates were then cultured with 1 ml of warmed OGD solution and incubated in air tight gas chambers for the indicated period exposed to 95% nitrogen, 5% CO~2~at 37°C with or without dexmedetomidine (0.001 to 0.1 nM) (Orion Pharm (UK) Ltd, NewburyBerkshire, UK)+/- atipamezole (1 nM). After OGD treatment, cells were removed from the gas chamber, the OGD solution was replaced with warmed culture medium and placed in a humidified 5% CO~2~incubator at 37°C for 24 hrs. Cell viability was assessed using an 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Merck KGaA, Darmstadt, Germany) assay \[[@B26]\].

Other cell cohorts were treated with dexmedetomidine (0.1 nM) in the absence of OGD with or without the highly selective inhibitors of PI3-Akt, LY294002 (50 μM), and mitogen-activated protein kinase (MAPK), PD98059 (50 μM), respectively.

Animals
-------

Ten-week-old male C57BL/6J mice weighing 20 to 25 g were housed in temperature and humidity-controlled cages with free access to sterile acidified water and irradiated food in a specific pathogen-free facility at Imperial College London. This study was approved by the ethics committee of Imperial College London and the UK Home Office (PPL: 70/6966) and all procedures were performed strictly under the United Kingdom Animals (Scientific Procedures) Act 1986.

Renal ischemia-reperfusion injury
---------------------------------

Dexmedetomidine (25 μg/kg, i.p., based on the previous organ protection studies \[[@B19],[@B27]\]) was administered 30 minutes before or immediately after renal ischemia-reperfusion injury (rIRI). One cohort was treated with the α2 adrenoceptor antagonist atipamezole (250 μg/kg, i.p. \[[@B19],[@B27]\]) prior to the administration of dexmedetomidine. The naive group and the rIRI group served as negative and positive controls, respectively. The animals were sacrificed 24 hr after rIRI. Kidneys were harvested for H&E and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. All assessments were made by an investigator who was blinded to the experimental protocols. rIRI was induced either by bilateral renal pedicle clamping for 25 minutes to produce moderate renal injury, or by right renal pedicle clamping for 40 minutes and left nephrectomy to produce life-threatening renal injury, under 1.5% isoflurane surgical anesthesia. Sham-operated mice had dissection as above, but with no occlusion of the renal vessel. The intra-abdominal temperature was maintained at 36 ± 0.1°C with a heating pad which was servo-adjusted by a temperature controller (Engineering Inc, Stamford, CT, USA) throughout the experiment. For survival experiments, mice were monitored on a daily basis with a scoring assay based on body weight, activity and general appearance as reported previously. Any animals that scored \> 7 were euthanized. All animals received 0.5 ml saline i.p. injection per every 6 hrs for the first 24 hrs after experiments.

Immunoblot
----------

Proteins were extracted from treated HK2 cells lines or frozen kidney samples by cell disruption in cell lysis buffer (New England Biolabs, Hitchin, Hertfordshire, UK) and sonication with an ultrasonic probe, followed by centrifugation at 10,000 g for 10 minutes at 4°C. The supernatant was collected for Western blotting. Samples containing 30 μg of extracted protein, as determined by the Bradford protein assay (BioRad, Hemel Hempstead Hertfordshire, UK), were loaded on a NuPAGE 4 to 12% Bis-Tris gel (Invitrogen, Paisley, UK) for protein fractionation by electrophoresis and then electro-transferred to a nitrocellulose membrane (Hybond ECL; Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). Blots were blocked with 5% non-fat dry milk in TBS (pH8.0, containing 0.1% Tween-20), and probed with appropriate antibodies (1:1,000 Akt, p-Akt and TLR4- all from followed Cell Signaling, Hitchin, Hertfordshire, UK; 1:100 TLR4- Santa Cruz, Wembley Middlesex, UK) by HRP-conjugated secondary antibodies (Cell Signaling) and visualisation with enhanced chemiluminescence (Cell Signaling). α-tubulin (1:2,000, Sigma, Dorset, UK) was used as internal control. Densitometry analysis were preformed and normalized with α-tubulin and then presented as percentage of control.

Histologic score
----------------

The sum score was calculated from the analysis of 10 cortical tubules/cross-section stained with H&E (10 sections/kidney) by using a modified scoring system \[[@B28]\]; 0, no damage. 1, mild damage: rounded epithelial cells and dilated tubular lumen; 2, moderate damage: flattened epithelial cells, loss of nuclear staining and substantially dilated lumen; 3, severe damage: destroyed tubules with no nuclear staining of epithelial cells.

Immunohistochemistry
--------------------

The second l death of tubular epithelial cells was detected by *in situ*TUNEL assay Obiogene, Cambridge, UK) according to the manufacturer\'s instructions. The fixed cryostat sections were washed with PBS and then treated with proteinase K (20 μg/ml) at room temperature for 15 minutes. For positive controls, sections were treated with nuclease (R&D System, Abingdon, UK) at 37°C for 15 minutes. The sections were quenched in 3% hydrogen peroxide in PBS for five minutes. The quenched sections were labelled with TDT enzyme at 37°C for 1 hour in a humidified chamber and subsequently incubated with anti-digoxygenin conjugated to horseradish peroxidase for 30 minutes at room temperature. They were then stained with DiAminoBenzidine (DAB). The sum of the TUNEL^+^cells in an objective grid from 10 areas of randomly selected renal cortex was counted under a 40 × objective lens by an investigator who was blinded to the experimental protocol.

The other fixed cryostat sections were incubated with 3% hydrogen peroxide for 30 minutes to quench endogenous peroxidase activity. Sections were blocked for 30 minutes in wash buffer phosphate buffered saline tween-20 containing 3% goat serum and then incubated at 4°C overnight with goat anti-mouse TLR-4 (Santa Cruz Biotechnology, Wembley, Middlesex, UK) diluted 1:250 in PBS and 1% goat serum. After washing with PBST, sections were incubated with biotinylated donkey anti-goat IgG (Santa Cruz) diluted 1:250 in PBS and then labelled with VectaStain Elite ABC solution (Vector Labs, Orton Southgate, Peterborough, UK). After further washes in PBS, staining was developed with DiAminoBenzidine (DAB) with nickel. Slides were washed in PBS buffer, dH20 and then in 100% ethanol for 10 minutes and xylene for 10 minutes before covered with cover glass for micrograph taken.

Plasma creatinine, urea and HMGB1
---------------------------------

Both creatinine and urea were measured in 100 μl of plasma with an Olympus AU640 analyzer (Diamond Diagnostics, Watford, UK). Plasma HMGB1 was measured by ELISA according to the manufacturer\'s instruction (IBL International GmbH, Hamburg, Germany)

Statistical analysis
--------------------

Statistical comparison was by ANOVA followed by *post hoc*Student-Newman Keul\'s test where appropriate. Survival was analyzed by Kaplan-Meier test. A *P*\< 0.05 was considered as statistically significant.

Results
=======

Dexmedetomidine confers *in vitro*protection via Akt activation
---------------------------------------------------------------

To determine whether dexmedetomidine provides reno-protection *in vitro*, we exposed HK2 cells, a well-characterized human kidney proximal tubular cell line to oxygen and glucose deprivation (OGD), established to mimic the ischemic phase of renal ischemic reperfusion injury in our previous studies \[[@B26]\]. Cell viability analysis using MTT assay showed a time-dependent induction of injury with marked cell death (60% reduction in viability) occurring after 180-minutes OGD (0.39 ± 0.07 versus 1.0 ± 0.04 of control; *P*\< 0.05) and was, therefore, used in subsequent experiments to determine the cytoprotective effects of dexmedetomidine (Figure [1A](#F1){ref-type="fig"}).

![**Renoprotective effect of dexmedetomidine (Dex) *in vitro***. Cultured HK2 cell injury was provoked with culture media deprived of oxygen and glucose (OGD). (**A**) The time course of OGD. (**B**) The dose response of Dex (0.001 to 0.1 nM) against OGD induced injury in the presence or absence of α~2~adrenoceptor antagonist, atipamazole (Atip) (1 nM). Data are expressed as mean ± SD (*n*= 5). \**P*\< 0.05; \*\**P*\< 0.01 vs zero time point or control.](cc10283-1){#F1}

Incubating HK2 cells with dexmedetomidine (0.001 to 0.1 nM) before OGD exposure dose-dependently inhibited injury (Figure [1B](#F1){ref-type="fig"}). Treatment with 0.1 nM dexmedetomidine increased cell viability to 94% (from 0.35 ± 0.10 to 0.94 ± 0.12; *P*\< 0.05), compared with the positive control (OGD). The cytoprotective effect of dexmedetomidine was abolished by co-treatment with the α2 adrenoceptor antagonist, atipamezole (1 nM), suggesting dexmedetomidine confers protection to renal epithelial cells *via*α~2~adrenoceptor activation. Treatment of naïve controls with either dexmedetomidine (0.1 nM) or atipamezole (1 nM) did not significantly decrease cell viability (0.8 ± 0.13 and 1.0 ± 0.25 respectively versus control). Therefore, neither dexmedetomidine nor atipamezole were cytotoxic to HK2 cells.

Activation of the Akt pathway plays a key role in cytoprotective signaling and has been demonstrated to ameliorate renal injury in IRI mice \[[@B29]\]. To determine whether dexmedetomidine activates Akt, we measured phosphorylated Akt (pAkt) levels in HK2 cells incubated with media containing 0.1 nM dexmedetomidine for 5, 10, 20, 30 and 45 minutes (Figure [2A](#F2){ref-type="fig"}). Dexmedetomidine induced significant increases in pAkt at all time-points; whereas, total Akt protein levels were not altered. The magnitude of Akt phosphorylation peaked after 20 minutes (2.91 ± 0.54 versus 1.0 ± 0.25 of control; *P*\< 0.01) and was used in subsequent experiments to identify upstream mediators of Akt activation. Atipamezole reduced, but could not completely abolish dexmedetomidine-induced phosphorylation of Akt, suggesting that pAkt activation may be partially dependent on α~2~adrenoceptors (Figure [2B](#F2){ref-type="fig"}). LY294002 and PD98059 have been shown to act *in vivo*as highly selective inhibitors of PI3-Akt and mitogen-activated protein kinase (MAPK) cascades respectively. LY294002 (50 μM) rather than PD98059 (50 μM) completely abolished dexmedetomidine-induced activation of Akt (0.6 ± 0.2 versus 1.7 ± 0.2 of Dex only; *P*\< 0.01), indicating that pAkt was generated in a PI3K-dependent manner.

![**Molecular mechanisms of renoprotection afforded by dexmedetomidine (Dex) *in vitro***. Cultured human kidney proximal tubular cells (HK2) cells were treated with dexmedetomidine and the time course of phospho-a serine/threonine protein kinase (pAkt) expression in culture homogenised supernatant was assessed with western blot (**A**) and its effect was abolished with the highly selective inhibitor of PI3-Akt, LY294002 (LY) (50 μM), but not by α2 adrenoceptor antagonist, atipamazole (Atip) (1 nM) and mitogen-activated protein kinase (MAPK), PD98059 (PD) (50 μM) (**B**). Data are expressed as the percentage of control (mean ± SD; *n*= 4). \**P*\< 0.05; \*\**P*\< 0.01 vs control; +*P*\< 0.05; ++*P*\< 0.01 vs Dex.](cc10283-2){#F2}

Dexmedetomidine reduces IRI pathological changes *in vivo*
----------------------------------------------------------

Next, we investigated whether dexmedetomidine provides protection against renal IRI in mice when the renal pedicle of both kidneys are clamped for 25 minutes. Twenty-four hours after IRI, kidneys and blood were harvested for histological assessment and for renal function (serum creatinine and urea), respectively. Histopathological assessment of cortical tubular damage was conducted by an investigator blinded to the experimental protocol. IRI significantly increased histopathological scoring (151 ± 45 versus 19 ± 9 of naive control; *P*\< 0.01), as illustrated by severe tubular lumen dilatation, flattened renal epithelial cells and loss of nuclear staining (Figure [3C](#F3){ref-type="fig"}). Pre- and post-treatment with dexmedetomidine (25 μg/kg) resulted in a 53% and 38% reduction in damage (72 ± 15; *P*\< 0.01 and 94 ± 19; *P*\< 0.05) compared with IRI group, respectively (Figure [3G](#F3){ref-type="fig"}). Atipamazole (250 μg/kg) given prior to dexmedetomidine pre-treatment significantly inhibited the reno-protective action (142 ± 38; *P*\< 0.01). Treatment of naïve animals with dexmedetomidine had no deleterious effects on kidney tissue (11 ± 9 versus 19 ± 9 of naïve control), in agreement with *in vitro*findings.

![***In vivo*renoprotection by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI)-histology**. Adult male mice were pretreated or post-treated with dexmedetomidine alone or in combination with α~2~adrenoceptor antagonist, atipamazole (Atip) (1 nM) followed by clamping of the bilateral renal pedicle for 25 minutes. Reno-protection of Dex was assessed histologically (H&E staining). Representative microphotographs were taken from a naïve control (**A**), Dex alone (**B**), IRI alone (**C**), pre-Dex treatment (25 μ/kg) +IRI (**D**), post-Dex treatment (25 microgm/kg) + IRI (**E**) and Atip + pre-Dex+IRI (**F**). (**G**) Quantification of histological scoring following IRI in mice pretreated as above. Bar = 100 μm. Data are mean ± SD (*n*= 5). \*\**P*\< 0.01 vs control. ++*P*\< 0.01 vs IRI.](cc10283-3){#F3}

To evaluate kidney damage at the cellular level, we used terminal deoxynucleotidyl transferase-mediated digoxigenindeoxyuridine nick-end labeling (TUNEL) staining to detect dead tubular cells. IRI significantly increased TUNEL-positive cells (85.0 ± 28.5 versus 6.2 ± 5.3 of naive control, *P*\< 0.01). Pre- and post-treatment with dexmedetomidine resulted in a 72% and 58% reduction in cell death (23.8 ± 7.5 and 35.2 ± 18.2; both *P*\< 0.01), compared to IRI mice, respectively (Figure [4](#F4){ref-type="fig"}). Cellular renoprotection was abolished when dexmedetomidine pre-treatment was preceded by atipamazole (89.0 ± 14.3; *P*\< 0.01). No difference in TUNEL staining was seen when dexmedetomidine was given to mice not subjected to renal injury (8.0 ± 2.3; NS versus naïve controls).

![***In vivo*reno-protection afforded by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI)- TUNEL staining**. Adult male mice were pretreated or post-treated with Dex alone or in combination with α~2~adrenoceptor antagonist, atipamazole (Atip) (1 nM) followed by clamping the bilateral renal pedicle for 25 minutes and the renoprotection of Dex was assessed with terminal deoxynucleotidyl transferase dUTP nick end (TUNEL) staining. Representative microphotographs taken from a naïve control (**A**), Dex alone (**B**), IRI alone (**C**), pre-Dex treatment (25 μg/kg) +IRI (**D**), post-Dex treatment (25 μg/kg) + IRI (**E**) and Atip + pre-Dex+IRI (**F**). (**G**) Quantification of TUNEL positive cell counting following IRI in mice pretreated as above. Bar = 100 μm. Data are mean ± SD (*n*= 5 to 6). \**P*\< 0.05, \*\**P*\< 0.01 vs control. ++*P*\< 0.01 vs IRI.](cc10283-4){#F4}

A similar pattern of changes were noted in renal function. After IRI, the plasma creatinine rose from 34.6 ± 2.2 to 81.8 ± 6.4 μM/L. Pre-treatment with dexmedetomidine was protective, with creatinine showing no significant difference from animals not subjected to renal injury. When dexmedetomidine pre-treatment was preceded by atipamazole, this abrogated the protective effect so that creatinine was significantly higher (85.8 ± 37.8; *P*\< 0.01) than that seen in the uninjured animals (Figure [5A](#F5){ref-type="fig"}). Similarly, IRI-induced increase in plasma urea (from 5.4 ± 0.2 to 27.9 ± 5.0 mM/L) was significantly reduced following pre-treatment with dexmedetomidine (18.22 ± 4.3; *P*\< 0.05), an effect that was completed abolished by atipamazole (30.0 ± 4.7; *P*\< 0.01) (Figure [5B](#F5){ref-type="fig"}).

![***In vivo*renoprotection afforded by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI)**. Adult male Mice were pretreated or post-treated with Dex alone or in combination with α~2~adrenoceptor antagonist, atipamazole (Atip) (1 nM) and the renoprotection of Dex was assessed with plasma creatinine (**A**) and urea measurement (**B**). Data are mean ± SD (*n*= 5 to 6). \* *P*\< 0.05, \*\**P*\< 0.01 vs control. +*P*\< 0.05, ++*P*\< 0.01 vs IRI.](cc10283-5){#F5}

Dexmedetomidine attenuates Toll-like Receptor 4 (TLR4) expression in tubular cells
----------------------------------------------------------------------------------

To investigate the molecular mechanisms of dexmedetomidine-induced renoprotection, we assessed toll-like receptor 4 (TLR4) expression *in situ*and its upstream mediator, high mobility group box-1 (HMGB1) nuclear protein in plasma. HMGB1 and TLR4 signaling play a pivotal role in the coordination of inflammatory responses in renal IRI \[[@B30],[@B31]\]. There was no detectable staining when primary antibody was omitted (data not shown) while TLR4 expression was at very minimal level in the naïve control (Figure [6A](#F6){ref-type="fig"}). However, marked increases in renal TLR4 expression were detected in IRI mice using *in situ*immunostaining (Figure [6B](#F6){ref-type="fig"}) and Western blot (Figure [6E](#F6){ref-type="fig"}). Pre-treatment with dexmedetomidine resulted in a dramatic decrease in TLR4 expression (Figure [6C](#F6){ref-type="fig"}) to a level even lower than that of control (Figure [6E](#F6){ref-type="fig"}), which was effectively restored to even the higher level than that in the control by atipamazole (Figure [6D](#F6){ref-type="fig"}). Similarly, plasma HMGB1 levels were dramatically elevated in IRI mice (from 25.9 ± 2.9 to 122.4 ± 40.3 pg/ml; *P*\< 0.001), compared to control. Pre- and post-treatment with dexmedetomidine significantly attenuated the rise in HMGB1 (58.1 ± 19.5 and 61.5 ± 28.3; both *P*\< .01) compared to IRI mice, respectively (Figure [6F](#F6){ref-type="fig"}). The protective effects of dexmedetomidine pre-treatment on HMGB1 upregulation were partially inhibited by atipamazole (61.5 ± 28.3; *P*\< 0.05) relative to IRI mice. Together, these findings suggest that HMGB1 and TLR4 pro-inflammatory signaling in renal IRI may be partially dependent on an α2 adrenoceptor-mediated mechanism. No change was seen in naïve mice treated with dexmedetomidine.

![**Anti-inflammatory effect afforded by dexmedetomidine (Dex) *in vivo***. Toll-like receptor 4 (TLR4) expression was assessed with *in situ*immunostaining and Western blot. Naïve control (**A**); Renal ischemia-reperfusion injury (IRI) (**B**); Dex+IRI (**C**); Atip (atipamazole) + pre-Dex+IRI (**D**) and Western blot (**E**). (**F**) Plasma level of High-mobility group protein B1 (HMGB1). Bar = 100 μm. Data are mean ± SD (*n*= 4). \*\**P*\< 0.01 vs control. +*P*\< 0.05, ++*P*\< 0.01 vs IRI.](cc10283-6){#F6}

Dexmedetomidine protects from renal failure
-------------------------------------------

To assess whether dexmedetomidine was also effective in the context of a more severe insult to renal function, we performed additional experiments in which the right renal pedicle was clamped for 40 minutes and the left kidney was removed. The mean value of plasma creatinine and urea rose more than seven-fold at 24 h after IRI (to 233.5 ± 34.1 μM/L and 62.1 ± 10.2 mM/L, respectively). Administration of dexmedetomidine either before or after IRI significantly attenuated the rise in creatinine and urea values (both *P*\< 0.01) relative to IRI controls (Figure [7A, B](#F7){ref-type="fig"}). Atipamezole treatment did not change creatinine and urea in IRI mice but significantly inhibited the renal protective effects of dexmedetomidine (*P*\< 0.001, all comparisons). Long-term survival (no signs of illness at seven days) was noted in 70% and 60% of animals treated with dexmedetomidine before and after renal IRI. By contrast, animals not treated with dexmedetomidine or receiving atipamezole combined dexmedetomidine fared much worse. Within three days, 65% of these animals were dead (either spontaneously or killed because of severe ill health measured against previously reported predefined criteria \[[@B28]\] and no animals survived beyond five days after IRI (*P*\< 0.001 versus pre- and post-dexmedetomidine groups; Figure [7C](#F7){ref-type="fig"}).

![**Renal failure induced by ischemia-reperfusion prevented by dexmedetomidine (Dex)**. Mice received Dex before or after IRI and kidney injury was induced by clamping the right renal pedicle for 40 minutes while the contralateral kidney was removed. The animals were allowed for 24 hrs before functional measurements (**A**- Creatinine; **B**- Urea), or up to seven days for the long term Kaplan-Meier survival curve analysis (*n*= 10) (**C**). Atip = atipamazole; IRI = Ischemia reperfusion injury. Data are mean ± SD (*n*= 5). \*\**P*\< 0.01 vs control. +*P*\< 0.05, ++*P*\< 0.01 vs IRI.](cc10283-7){#F7}

Discussion
==========

Our work showed that dexmedetomidine induced a sustained up-regulation of phospho-Akt and protected against oxygen-glucose deprivation in a human kidney cell line; its effects were blocked by atipamezole. *In vivo*, dexmedetomidine attenuated the HMGB-1/TLR-4 pathway, preserving tubular architecture and reducing cell death. Associated with the improved histological findings, the level of renal dysfunction was minimized and renal failure was prevented after severe IRI resulting in improved survival. The organ-protective effect was abolished with α~2~adrenoreceptor antagonist, indicating that dexmedetomidine acted in an α~2~adrenoreceptor dependent manner.

Our data demonstrated a significantly increased expression of phospho-Akt in cultured tubular cells after treatment with dexmedetomidine (Figure [2](#F2){ref-type="fig"}). This was blocked partially by an α~2~adrenoceptor antagonist and significantly reduced by a PI3K inhibitor, indicating that the dexmedetomidine activates Akt *via*both α~2~adrenoceptor dependent and independent-PI3K coupling. In summation, we consider it likely that the activation of PI3K-Akt is one of the survival cascades activated by dexmedetomidine to induce cytoprotection (Figure [1](#F1){ref-type="fig"}). The PI3K-Akt pathway promotes cell survival by phosphorylating the proapoptotic Bcl-2-associated death promotor (BAD) and up-regulating the expression of anti-apoptotic Bcl-2 and Bcl-xl \[[@B32]\], inhibiting the caspase-controlled intrinsic apoptotic pathway \[[@B33]\]. Consistent with our findings, dexmedetomidine has been shown to decrease the expression of pro-apoptotic factors such as caspase-3 \[[@B34]\] and Bax whilst increasing the expression of anti-apoptotic Bcl-2 and Mdm-2 \[[@B35]\] in the brain. Akt signaling has previously been shown to be critical to recovery from renal IRI injury and therefore, it can be concluded that dexmedetomidine protection may involve Akt signaling.

In addition to its cytoprotective effects, our studies demonstrated that dexmedetomidine suppressed the TLR-4 mediated inflammatory circuitry. Expression of TLR-4 has been shown to be triggered through endogenous ligands, including damage-associated molecular patterns (DAMPs) and cytokines. High mobility group box 1 (HMGB-1) is a potent DAMP released from dying cells during tissue ischemia. It binds to TLR-4 initiating down-stream NF-κB signaling cascade \[[@B36]\] substantially augmenting the synthesis of pro-inflammatory cytokines such as TNF-α and IL-1β \[[@B37]\]. Recent work by Wu *et al*., \[[@B38]\] demonstrated that TLR4-deficient or the adaptor molecule myD88-deficient mice were protected from both kidney dysfunction and histological damage induced by renal IRI. Generation of pro-inflammatory cytokine (IL-6, IL-1β, and TNF-α) and chemokines (MIP-2 and MCP-1) was inhibited, together with a parallel decline of macrophage and neutrophil infiltration. Pre-treatment of dexmedetomine resulted in almost complete attenuation of TLR-4 expression associated with decreased cell death of tubular epithelial cells. We propose that dexmedetomidine may have prevented the increased expression of TLR-4 by attenuating tissue injury (evidenced by lower systemic HMGB1 levels and reduced TUNEL staining) and through co-existent anti-inflammatory actions \[[@B39]-[@B41]\] (Figure [8](#F8){ref-type="fig"}). Herein, we did not further explore the well described anti-inflammatory effects of dexmedetomidine (beyond HMGB1 levels); however, dexmedetomidine reduces systemic levels of IL-6 and TNF-α following lipopolysaccharide infusion in rats \[[@B39]\] and following cardiac surgery \[[@B40]\] and sepsis in humans \[[@B42]\]. It is, therefore, plausible that the anti-inflammatory actions of dexmedetomidine contributed to the reduced TLR-4 expression following renal ischemia.

![**Putative mechanism of dexmedetomidine (Dex) renoprotection**. Dexmedetomidine stimulates the α~2~adrenoceptor (α~2~) to induce phosphoinositol-3-kinase (PI3K) phosphorylation of Akt (pAKT) and activation of the downstream cell survival signaling to block ischemia induced injury. Ischemia is denoted by the \"flash\" symbol. Improved cellular survival leads to reduced release of the damage-associated molecular pattern High-mobility group protein B1 (HMGB1). Reduced HMGB1 decreases the inflammatory drive that both increases Toll-like receptor 4 (TLR4) expression and activates the detrimental effect of TLR4 signaling in renal ischemia. Co-receptors for HMGB1 include TLRs and Interleukin-1 (IL-1) receptor; when HMGB1 binds to the ligand (for example, lipopolysaccharide or IL-1) this augments subsequent proinflammatory signaling. Therefore, dexmedetomidine acts proximally in the pathway (at the cytoprotective level) to prevent the elaboration of renal ischemic injury. \'Lightening bolt\' denotes ischemia. \'Square\' denotes HMGB1 co-receptor.](cc10283-8){#F8}

Our study showed a marked improvement in renal morphology and function with reduced nitrogenous waste accumulation following treatment of dexmedetomidine. This protection was attenuated by atipamezole, an α~2~adrenoreceptor antagonist, confirming dependence on α~2~-adrenoceptor agonism. Similarly dexmedetomidine\'s neuroprotective effect is mediated by α~2~-adrenoceptor signaling \[[@B19]\]. Consistent with evidence from neuroprotection, our *in vitro*data suggest that the primary effect of dexmedetomidine is cytoprotection; nonetheless, *in vivo*it is likely that improved renal blood flow may have contributed to improved renal function and recovery from ischemia. Indeed modulation of vasoreactivity, through reduced sympathetic drive, has been shown to be an important mechanism of α~2~adrenoceptor agonist renoprotection \[[@B21],[@B24],[@B25]\]. In a model of radiocontrast nephropathy α~2~-adrenoceptor activation with dexmedetomidine resulted in improved renal function, an effect attributable to improved renal blood flow \[[@B21]\]. However, α~2~-adrenoceptor activation was not associated with cytoprotection from radiocontrast exposure *in vitro*\[[@B21]\] indicating that there are differing mechanisms of radiocontrast and ischemic injury in the kidney. The local responses to α~2~-adrenoceptor activation in the kidney include vasodilatation \[[@B21]\], inhibition of renin release, increased glomerular filtration and increased secretion of sodium and water \[[@B43],[@B44]\]. α~2~-adrenoceptor agonists may preserve glomerular filtration by preventing reduced renal blood flow following reperfusion associated vasospasm. They may also provoke diuresis by opposing the activity of arginine vasopressin in the collecting duct as well reducing aquaporin expression \[[@B45]\]. In combination, cytoprotection, improved glomerular filtration and diuretic actions may have improved renal function following ischemic injury.

α~2~-adrenoceptor agonists have diverse utility in the perioperative period; their renoprotective qualities are complemented by their analgesic qualities that reduce the necessity of other analgesics. Reduced use of non-steroidal anti-inflammatory drugs and opioids may be of particular interest as non-steroidal anti-inflammatory drugs increase the risk of AKI and opioids accumulate in AKI. Furthermore, the hemodynamic control, cardioprotection and mild diuretic properties of α~2~-adrenoceptor agonists may indirectly support renal function. We consider there are multiple reasons to consider a large prospective randomized controlled trial of the reno-protective qualities of α~2~-adrenoceptor agonists.

Conclusions
===========

AKI associated with ischemia-reperfusion injury is a significant contributor to morbidity and mortality in the perioperative period. dexmedetomidine provides renoprotection against renal IRI whether given as a prophylactic or therapeutic measure. Our data complement preliminary clinical data showing that prophylactic clonidine treatment prevented renal dysfunction attributable to cardiac surgery and that dexmedetomidine improved renal function following thoracic surgery. If our data can be extrapolated to clinical settings, dexmedetomidine may prove protective against IRI associated acute renal failure.

Key messages
============

• Acute kidney injury following surgery significantly increases mortality with no proven preventative therapy.

• The α~2~adrenoceptor agonist dexmedetomidine has organoprotective properties.

• Dexmedetomidine activates cell survival signal pAKT *via*α~2~adrenoceptors to reduce cell death and HMGB1 release and subsequently inhibits TLR4 signaling to provide renoprotection.

• Dexmedetomidine may have both cytoprotective and anti-inflammatory effects to protect against renal injury following ischemia-reperfusion.

• If our data can be extrapolated to clinical settings, dexmedetomidine may prove protective against IRI associated acute renal failure.

Abbreviations
=============

AKI: acute kidney injury; AKT: a serine/threonine protein kinase; DAMPs: damage-associated molecular patterns; Dex: dexmedetomidine; HK2: human kidney proximal tubular cells; HMGB-1: high-mobility group protein B1; IL: interleukin; IRI: ischemia-reperfusion injury; MTT: 3- (4,5-Dimethyl-2-thiazolyl) -2, 5-diphenyl -2H- tetrazolium bromide; NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells; OGD: oxygen glucose deprivation; PI3K: phosphatidylinositol 3-kinase; TLR-4: toll-like receptor 4; TNF-α: tumor necrosis factor α; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling.
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